Suppr超能文献

微管细胞骨架与DNA合成的起始

The microtubular cytoskeleton and the initiation of DNA synthesis.

作者信息

Thyberg J

出版信息

Exp Cell Res. 1984 Nov;155(1):1-8. doi: 10.1016/0014-4827(84)90761-4.

Abstract

Depending on cell type and mode of growth stimulation, an intact cytoplasmic microtubule system may either support or suppress passage through the prereplicative G1 phase (growth and maturation) and entrance into the S phase (DNA synthesis) of the cell cycle. In peripheral blood lymphocytes exposed to mitogenic lectins, colchicine and other antimicrotubular drugs inhibit blast transformation and initiation of DNA synthesis. The inhibitory effect is not due to decreased cellular binding of lectin or lack of generation of a stimulatory signal. Rather, it can be explained by an inability of the cells to pass through the G1 phase at a normal rate in the absence of cytoplasmic microtubules. The formation of new organelles and the growth in cell size that occur during this phase is markedly delayed by the drugs. For example, the Golgi complex, an organelle system that participates in membrane biogenesis and other basic cellular functions, is reduced in size and structurally disorganized. In cells with a shorter prereplicative phase, such as fibroblasts and smooth muscle cells, antimicrotubular drugs inhibit DNA synthesis in growth-arrested cultures exposed to optimal concentrations of serum, thrombin or platelet-derived growth factor (PDGF). On the other hand, antimicrotubular drugs stimulate DNA replication in serum-free cultures and enhance the stimulatory effect of insulin, epidermal growth factor (EGF), fibroblast growth factor (FGF), and prostaglandin F2 alpha on entrance into S phase. Moreover, stabilization of cytoplasmic microtubules with taxol has been found to block microtubule disassembly and initiation of DNA synthesis by colchicine and to inhibit thrombin- and EGF-stimulated DNA synthesis under serum-free conditions. These findings suggest that partial microtubule disassembly is an inherent step in the reactions that precede DNA replication and mitosis. However, the cell biological and molecular details of these reactions and the exact role of microtubules remain enigmatic.

摘要

根据细胞类型和生长刺激模式,完整的细胞质微管系统可能支持或抑制细胞周期中复制前G1期(生长和成熟)的进程以及进入S期(DNA合成)。在暴露于促有丝分裂凝集素的外周血淋巴细胞中,秋水仙碱和其他抗微管药物会抑制胚细胞转化和DNA合成的起始。这种抑制作用并非由于细胞对凝集素的结合减少或缺乏刺激信号的产生。相反,这可以解释为在没有细胞质微管的情况下,细胞无法以正常速率通过G1期。在此阶段发生的新细胞器形成和细胞大小增长会被这些药物显著延迟。例如,高尔基体作为参与膜生物合成和其他基本细胞功能的细胞器系统,其大小会减小且结构紊乱。在复制前期较短的细胞中,如成纤维细胞和平滑肌细胞,抗微管药物会抑制暴露于最佳浓度血清、凝血酶或血小板衍生生长因子(PDGF)的生长停滞培养物中的DNA合成。另一方面,抗微管药物会刺激无血清培养物中的DNA复制,并增强胰岛素、表皮生长因子(EGF)、成纤维细胞生长因子(FGF)和前列腺素F2α对进入S期的刺激作用。此外,已发现用紫杉醇稳定细胞质微管可阻止微管解聚以及秋水仙碱引发的DNA合成,并在无血清条件下抑制凝血酶和EGF刺激的DNA合成。这些发现表明,部分微管解聚是DNA复制和有丝分裂之前反应中的一个固有步骤。然而,这些反应的细胞生物学和分子细节以及微管的确切作用仍然是个谜。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验